

AUG. 10. 2005 1:26PM AVENTIS US PAT DEPT
TO: US CENTRALIZED USPTO

RECEIVED
CENTRAL FAX CENTER

NO. 7413 P. 1/11

AUG 10 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

		Application Number	10/786,483
		Filing Date	February 25, 2004
		First Named Inventor	Jesús BENAVIDES et al.
		Art Unit	1617
		Examiner Name	CHONG, Yong Soo
Total Number of Pages in This Submission	11 pgs	Attorney Docket Number	ST01024 US CNT

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): <input type="checkbox"/>
Remarks 1. Response to Restriction/Election Requirement - 4 pgs. 2. Copy of the International Preliminary Examination Report of PCT/FR02/02945 - 6 pgs.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Balaram Gupta		
Date	August 10, 2005	Reg. No.	40,009

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: 11 pgs)

Signature			
Typed or printed name	Brian Pritchett	Date	August 10, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**RECEIVED
CENTRAL FAX CENTER**

AUG 10 2005

PATENT
Docket No.: ST01024-US-CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Jesus Benavides, et al.

Serial No.: 10/786,483

Filed: February 25, 2004

Examiner: Chong, Yong Soo

Art Unit: 1617

Title: Combination of a CB1 Receptor Antagonist and of a Product Which Activates Dopaminergic Neurotransmission in the Brain, the Pharmaceutical Compositions Comprising Them and their Use in the Treatment of Parkinson's Disease

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile at 571-273-8300 to the Commissioner for Patents, Washington, D.C. 20231, on

August 10, 2005
Date of transmission

Brian Aitken
Signature

Response to Restriction/Election Requirement Under 35 U.S.C. § 121

Sir:

This is in response to the Office Action, dated, July 13, 2005, having a response due by, August 15, 2005 in the above-identified patent application. It is respectfully requested that the following provisional election, and the remarks be entered in this case.

PROVISIONAL ELECTION:

Applicants provisionally elect with traverse the invention Group I, claims 1-10, and 15-24, drawn to a composition comprising one or more CB1 antagonist azetidine derivative of formula I.

ELECTION OF A COMPOUND WITHIN ELECTED SUB-SPECIES:

Applicants provisionally elect with traverse a single compound falling within the scope of invention Group I to be 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)-(methylsulfonyl)methylene]-azetidine, which is used as one of the components of the combination in Example 1, see pages 26 to 30 of the specification.